Armin Rashidi1, Thomas Kaiser2,3, Carolyn Graiziger4, Shernan G Holtan1, Tauseef Ur Rehman4, Daniel J Weisdorf1, Gary M Dunny5, Alexander Khoruts3,4, Christopher Staley2,3. 1. Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota. 2. Department of Surgery, University of Minnesota, Minneapolis, Minnesota. 3. BioTechnology Institute, University of Minnesota, St. Paul, Minnesota. 4. Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Minnesota, Minneapolis, Minnesota. 5. Department of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota.
Abstract
BACKGROUND: In the field of malignant hematology, most microbiome studies have focused on recipients of allogeneic hematopoietic cell transplantation (allo-HCT). As a result, this population has remained the primary target for novel microbiota therapeutics. Because the types of insults to the microbiome are similar during hematopoietic cell transplantation and intensive antileukemia therapy, this study evaluated whether the dysbiosis states are similar in the 2 settings. METHODS: This study compared gut microbiota assemblages and community domination states in 2 cohorts of patients: patients with intensively treated acute leukemia (AL) and allo-HCT recipients. 16S ribosomal RNA gene profiling of thrice weekly stool samples was performed. Linear discriminant analysis effect size was used to determine differentially abundant taxa in groups of interest, and mixed modes were used to determine the predictors of microbiome states. RESULTS: Microbiome changes in both cohorts were characterized by a marked loss of diversity and domination of low-diversity communities by Enterococcus. In the AL cohort, the relative abundance of Lactobacillus was also inversely correlated with diversity. Communities dominated by these genera were compositionally different. CONCLUSIONS: Similarities in microbiota assemblages between the 2 cohorts support a broader scope for microbiota-directed therapeutics than previously considered, whereas specific differences suggest a personalized aspect to such therapeutics with the possibility of a differential response.
BACKGROUND: In the field of malignant hematology, most microbiome studies have focused on recipients of allogeneic hematopoietic cell transplantation (allo-HCT). As a result, this population has remained the primary target for novel microbiota therapeutics. Because the types of insults to the microbiome are similar during hematopoietic cell transplantation and intensive antileukemia therapy, this study evaluated whether the dysbiosis states are similar in the 2 settings. METHODS: This study compared gut microbiota assemblages and community domination states in 2 cohorts of patients: patients with intensively treated acute leukemia (AL) and allo-HCT recipients. 16S ribosomal RNA gene profiling of thrice weekly stool samples was performed. Linear discriminant analysis effect size was used to determine differentially abundant taxa in groups of interest, and mixed modes were used to determine the predictors of microbiome states. RESULTS: Microbiome changes in both cohorts were characterized by a marked loss of diversity and domination of low-diversity communities by Enterococcus. In the AL cohort, the relative abundance of Lactobacillus was also inversely correlated with diversity. Communities dominated by these genera were compositionally different. CONCLUSIONS: Similarities in microbiota assemblages between the 2 cohorts support a broader scope for microbiota-directed therapeutics than previously considered, whereas specific differences suggest a personalized aspect to such therapeutics with the possibility of a differential response.
Authors: Sonia T Anand; Kelli K Ryckman; Rebecca J Baer; Mary E Charlton; Patrick J Breheny; William W Terry; Kord Kober; Scott Oltman; Elizabeth E Rogers; Laura L Jelliffe-Pawlowski; Elizabeth A Chrischilles Journal: J Matern Fetal Neonatal Med Date: 2021-05-12
Authors: Armin Rashidi; Maryam Ebadi; Tauseef Ur Rehman; Heba Elhusseini; Hossam Fathi Halaweish; Thomas Kaiser; Shernan G Holtan; Alexander Khoruts; Daniel J Weisdorf; Christopher Staley Journal: Blood Adv Date: 2022-06-14
Authors: Armin Rashidi; Maryam Ebadi; Tauseef Ur Rehman; Heba Elhusseini; Hossam Halaweish; Thomas Kaiser; Shernan G Holtan; Alexander Khoruts; Daniel J Weisdorf; Christopher Staley Journal: Sci Data Date: 2022-08-02 Impact factor: 8.501
Authors: Mohammad Haneef Khan; Guillaume C Onyeaghala; Armin Rashidi; Shernan G Holtan; Alexander Khoruts; Ajay Israni; Pamala A Jacobson; Christopher Staley Journal: Gut Microbes Date: 2022 Jan-Dec
Authors: Harika Nalluri-Butz; Matthew C Bobel; Julia Nugent; Sonja Boatman; Ryan Emanuelson; Genevieve Melton-Meaux; Robert D Madoff; Cyrus Jahansouz; Christopher Staley; Wolfgang B Gaertner Journal: Sci Rep Date: 2022-06-22 Impact factor: 4.996